Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.
暂无分享,去创建一个
A. Jakubowiak | S. Malek | N. Donato | M. Young | M. Talpaz | L. Peterson | H. Showalter | Duxin Sun | Hanshi Sun | Malathi Kandarpa | S. Courtney | Yihong Liu | M. Ermann | H. Potu
[1] N. Donato,et al. Emerging potential of therapeutic targeting of ubiquitin-specific proteases in the treatment of cancer. , 2014, Cancer research.
[2] N. Donato,et al. Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway , 2014, Oncotarget.
[3] M. Gleave,et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer , 2014, Proceedings of the National Academy of Sciences.
[4] A. Levitzki,et al. Degrasyn-like symmetrical compounds: possible therapeutic agents for multiple myeloma (MM-I). , 2014, Bioorganic & medicinal chemistry.
[5] Robert Mah,et al. Drug discovery considerations in the development of covalent inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[6] D. Rigden,et al. Deubiquitylases from genes to organism. , 2013, Physiological reviews.
[7] Nathanael S Gray,et al. Developing irreversible inhibitors of the protein kinase cysteinome. , 2013, Chemistry & biology.
[8] Bart Barlogie,et al. Advances in Biology and Therapy of Multiple Myeloma , 2013, Springer New York.
[9] M. Kirschner,et al. Deubiquitinase FAM/USP9X Interacts with the E3 Ubiquitin Ligase SMURF1 Protein and Protects It from Ligase Activity-dependent Self-degradation , 2012, The Journal of Biological Chemistry.
[10] J. Yap,et al. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition , 2012, BMC Cancer.
[11] Ling Zhang,et al. The deubiquitinating protein USP24 interacts with DDB2 and regulates DDB2 stability , 2012, Cell cycle.
[12] Parantu K. Shah,et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.
[13] F. Bunz,et al. Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil , 2012, Cancer biology & therapy.
[14] A. Kalgutkar,et al. Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.
[15] Mårten Fryknäs,et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy , 2011, Nature Medicine.
[16] F. Colland,et al. Ubiquitin-specific proteases as cancer drug targets. , 2011, Future oncology.
[17] Adrian Whitty,et al. The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.
[18] N. Donato,et al. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. , 2011, Blood.
[19] N. Donato,et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. , 2010, Cancer research.
[20] W. Bornmann,et al. Degrasyn Potentiates the Antitumor Effects of Bortezomib in Mantle Cell Lymphoma Cells In vitro and In vivo: Therapeutic Implications , 2010, Molecular Cancer Therapeutics.
[21] F. Bazan,et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival , 2010, Nature.
[22] David Komander,et al. Breaking the chains: structure and function of the deubiquitinases , 2009, Nature Reviews Molecular Cell Biology.
[23] D. Lane,et al. Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53* , 2009, Journal of Biological Chemistry.
[24] N. Donato,et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. , 2008, Journal of the National Cancer Institute.
[25] M. Kaminski,et al. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. , 2007, Blood.
[26] M. Kaminski,et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. , 2007, Blood.
[27] N. Donato,et al. Degrasyn activates proteasomal-dependent degradation of c-Myc. , 2007, Cancer research.
[28] David R Williams,et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.
[29] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[30] R. Bataille,et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival , 2005, Leukemia.
[31] K. Sikora,et al. Leukemia , 1984, British Journal of Cancer.